Erasca (NASDAQ:ERAS – Get Free Report) issued its earnings results on Monday. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.12), Zacks reports.
Erasca Stock Performance
Shares of Erasca stock traded down $0.01 during trading on Wednesday, hitting $2.59. 1,670,854 shares of the company’s stock were exchanged, compared to its average volume of 1,515,694. The stock has a market capitalization of $449.00 million, a price-to-earnings ratio of -3.12 and a beta of 1.17. The business has a 50-day simple moving average of $2.58 and a 200-day simple moving average of $2.26. Erasca has a 52-week low of $1.51 and a 52-week high of $3.45.
Insider Buying and Selling at Erasca
In related news, Director Alexander W. Casdin purchased 80,000 shares of the business’s stock in a transaction on Tuesday, May 21st. The shares were bought at an average cost of $2.27 per share, with a total value of $181,600.00. Following the transaction, the director now owns 573,974 shares of the company’s stock, valued at $1,302,920.98. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 21.50% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
Read Our Latest Report on Erasca
About Erasca
Erasca, Inc, a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma.
Further Reading
- Five stocks we like better than Erasca
- The Risks of Owning Bonds
- Brinker International’s Price Dip is an Appetizing Entry Point
- About the Markup Calculator
- 3 Stocks That Could Beat the September Blues
- What Makes a Stock a Good Dividend Stock?
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Erasca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erasca and related companies with MarketBeat.com's FREE daily email newsletter.